Order Article Reprints

Cavalieri S, Serafini MS, Carenzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, et al. An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer. Cells. 2022; 11(19):3176. https://doi.org/10.3390/cells11193176

Cavalieri, Stefano, Mara Serena Serafini, Andrea Carenzo, Silvana Canevari, Deborah Lenoci, Federico Pistore, Rosalba Miceli, Stefania Vecchio, Daris Ferrari, Cecilia Moro, and et al. 2022. "An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer" Cells 11, no. 19: 3176. https://doi.org/10.3390/cells11193176

Cavalieri, S., Serafini, M. S., Carenzo, A., Canevari, S., Lenoci, D., Pistore, F., Miceli, R., Vecchio, S., Ferrari, D., Moro, C., Sponghini, A., Caldara, A., Rocca, M. C., Secondino, S., Moretti, G., Denaro, N., Caponigro, F., Vaccher, E., Rinaldi, G., ... De Cecco, L. (2022). An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer. Cells, 11(19), 3176. https://doi.org/10.3390/cells11193176